GlassScriptPhysician profile
Lisa D Boyle
NPI 1740206309
$29,703.27
in general payments reported to CMS, 2019-2025
25 companies · $724 in 2025
The $724 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $45.44 · 2021: $10K · 2022: $16K · 2023: $2,434 · 2024: $745 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Food and Beverage: $1,404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Food and Beverage | $1,403.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $25,023.41 | 2019-2022 | |
| Abbvie INC. | $2,786.02 | 2019-2025 | |
| Exeltis, USA INC. | $334.18 | 2022-2025 | Slynd |
| Coopersurgical, INC. | $153.00 | 2019-2025 | Paragard T 380a |
| Myriad Women'S Health, INC. | $138.15 | 2023 | |
| Sumitomo Pharma America, INC. | $126.29 | 2023-2025 | Myfembree, Gemtesa |
| Galderma Laboratories, L.P. | $124.48 | 2025 | |
| Astellas Pharma US INC | $122.71 | 2023-2024 | Veozah |
| Agile Therapeutics, INC. | $110.26 | 2021-2022 | |
| Sage Therapeutics, LLC | $109.94 | 2024-2025 | Zurzuvae |
| Myovant Sciences INC. | $105.24 | 2022 | |
| Mayne Pharma Commercial LLC | $74.64 | 2021-2023 | |
| Therapeuticsmd, INC. | $69.65 | 2019-2022 | |
| Hologic Sales and Service, LLC | $68.71 | 2022 | |
| Pfizer INC. | $54.16 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $49.78 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $44.56 | 2020-2024 | |
| Mylan Pharmaceuticals INC. | $39.99 | 2022 | |
| Supernus Pharmaceuticals, INC. | $37.99 | 2025 | Qelbree |
| Shield Therapeutics INC | $24.69 | 2024 | |
| Avion Pharmaceuticals | $23.61 | 2019-2020 | |
| Exact Sciences Corporation | $23.60 | 2023 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $20.53 | 2024 | Injectafer |
| Becton, Dickinson and Company | $18.94 | 2020 | |
| Boston Scientific Corporation | $18.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.